Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02147873 · ClinicalTrials.gov registry record · Phase 2
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
A Phase 2 study, sponsored by TetraLogic Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 118
- Enrollment target
NCT02147873: Clinical Trial Phase 2 study, sponsored by TetraLogic Pharmaceuticals.
NCT02147873 is a Phase 2 study that was terminated before completion, run by TetraLogic Pharmaceuticals. The registered enrollment target is 118 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (11% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02147873, a Phase 2 study, was terminated before completion, sponsored by TetraLogic Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 118 participants
- Enrollment target
Study Summary
This is a randomized double blind placebo controlled study of azacitidine with or without birinapant in subjects with higher risk Myelodysplastic syndrome, secondary MDS or myelomonocytic leukemia (CMMoL) who are naïve, to azacitidine therapy. Pre-clinical and mechanistic studies support that azacitidine may modulate pathways that enable birinapant-mediated anti-tumor activity.
Interventions
- DRUG Placebo
- DRUG Azacitidine
- DRUG birinapant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2014-06 |
| Est. Completion | 2016-06 |
| Phase | Phase 2 |
Why NCT02147873 stopped before completion
NCT02147873 is an interventional study that assigns participants to a tested intervention. The registered 118 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (11% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02147873 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02147873 about?
NCT02147873 is a clinical study titled "Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL". This is a randomized double blind placebo controlled study of azacitidine with or without birinapant in subjects with higher risk Myelodysplastic syndrome, secondary MDS or myelomonocytic leukemia (CMMoL) who are naïve, to azacitidine therapy. Pre-clinical and mechanistic studies support that azacit...
What is the current status of trial NCT02147873?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 118 participants. The study started on 2014-06. Estimated completion is 2016-06.
What interventions are being tested in trial NCT02147873?
The interventions under investigation include: Placebo (DRUG), Azacitidine (DRUG), birinapant (DRUG).
Who is sponsoring clinical trial NCT02147873?
This trial is sponsored by TetraLogic Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02147873's enrollment target sits among peer trials
118 618th of 2000 higher than 1,378 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03821623 · 118 participants · Phase 2
Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
- NCT04040959 · 118 participants · Phase 2
Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD
- NCT04696029 · 118 participants · Phase 2
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
- NCT05223192 · 118 participants · NA
The Effects of Entrainment on Respiratory Stability and Cerebral Oxygenation in Preterm Infants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia